Evidence map›Paper›PMID 41998740›Full record

ArticleAlzheimer's research & therapy2026

Self-reported sleep quality and longitudinal amyloid burden in clinically unimpaired adults from the AMYPAD PNHS study.

Núria Tort-Colet, Laura Stankeviciute, Ana Fernández-Arcos, Natalia Soldevila-Domenech, Gonzalo Sánchez-Benavides, Mahnaz Shekari, David Vállez García, Daniele Altomare, Frederik Barkhof, Mercè Boada and 25 more

Abstract read
In one paragraph

Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Núria Tort-ColetBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain. ntort@barcelonabeta.org.
Laura StankeviciuteDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Västra Götalands, Sweden.
Ana Fernández-ArcosBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Natalia Soldevila-DomenechBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Gonzalo Sánchez-BenavidesBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Mahnaz ShekariBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
David Vállez GarcíaBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Daniele AltomareDepartment of Business Economics Health and Social Care (DEASS), Competence Centre On Ageing (CCA), University of Applied Sciences and Arts of Southern Switzerland (SUPSI), Manno, Switzerland.
Frederik BarkhofDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands.
Mercè BoadaAce Alzheimer Center Barcelona -Universitat Internacional de Catalunya, Barcelona, Spain.
Christopher BuckleyGE HealthCare, Amersham, UK.
Lyduine E CollijDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands.
Anouk den BraberDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Gill FarrarGE HealthCare, Amersham, UK.
Lisa FordJohnson & Johnson Innovative Medicine, Titusville, NJ, USA.
Giovanni B FrisoniLaboratory of Neuroimaging of Aging (LANVIE), Université de Genève, Geneva, Switzerland.
Rossella GismondiLife Molecular Imaging, Life Molecular Imaging, Berlin, Germany.
Juan D GispertBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Sylke GrootoonkIXICO, London, UK.
Bernard J HanseeuwInstitute of Neuroscience (IONS), Université Catholique de Louvain, Brussels, Belgium.
Frank JessenGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Emma S LuckettDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands.
Richard ManberIXICO, London, UK.
Marta MarquiéAce Alzheimer Center Barcelona -Universitat Internacional de Catalunya, Barcelona, Spain.
Anja MettGE HealthCare, Amersham, UK.
Lisa QuenonInstitute of Neuroscience, UCLouvain, Brussels, Belgium.
Craig RitchieCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Mark E SchmidtJanssen Research and Development, Beerse, Belgium.
Michael SchöllWallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Göteborg, Sweden.
Andrew W StephensLife Molecular Imaging, GmbH, Berlin, Germany.
Rik VandenbergheNeurology Service, University Hospital Leuven, Louvain, Belgium.
Pieter J VisserDepartment of Neurology and Alzheimer Center, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands.
Robin WolzIXICO, London, UK.
Oriol Grau-RiveraBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
AMYPAD Consortium

Funding

Instituto de Salud Carlos III PI19/00117Instituto de Salud Carlos III (ISCIII) CP23/00039 (Miguel Servet contract)Ministerio de Ciencia e Innovación IJC2020-043417-IMinisterio de Ciencia e Innovación PID2020-119556RA-I00
6 · The paper itself

Abstract

backgroundPoor self-reported sleep quality is associated with cognitive impairment. Alzheimer’s disease (AD) patients present sleep disruptions decades before they start to decline clinically. Similarly, amyloid-β (Aβ) starts accumulating during the preclinical phase of the disease. This study investigated associations between self-reported sleep quality and Aβ burden longitudinally in clinically unimpaired (CU) adults.

methodsFour hundred seventeen CU adults from the AMYPAD PNHS cohort were included, with baseline self-reported sleep quality assessments (Pittsburgh Sleep Quality Index, PSQI) and longitudinal Aβ PET scans. Participants were categorized by baseline Aβ levels as negative (A-), grey-zone (GZ), or positive (A+). Linear mixed-effects (LME) models tested the association between baseline sleep quality and Aβ burden over time, including interaction effects with baseline Aβ status.

resultsGlobal PSQI score was not associated with Aβ burden over time in the entire group. However, a significant interaction with baseline Aβ status was found, whereby poorer subjective sleep quality was linked to accelerated Aβ accumulation in GZ participants.

conclusionsPoorer subjective sleep quality is associated with faster Aβ accumulation in CU individuals with intermediate Aβ levels, highlighting sleep as a potential target for early AD prevention and identifying an optimal intervention window.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesSelf ReportSleep QualityAgedAsymptomatic DiseasesBrainFemaleFollow-Up StudiesHumansLongitudinal StudiesMaleMiddle AgedPositron-Emission TomographyProspective StudiesRadiopharmaceuticalsAmyloid beta-PeptidesRadiopharmaceuticalsAlzheimer’s disease; preclinical Alzheimer’s diseaseAmyloid PETSleep

Identifiers

PMID41998740
PMCPMC13220363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.